Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential downside of 0.22% from the company’s previous close.

Several other equities analysts have also recently issued reports on REGN. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a report on Monday, February 2nd. HSBC initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 target price on the stock. Scotiabank lifted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $796.52.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $766.66 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The company has a 50 day moving average price of $771.45 and a 200 day moving average price of $685.39. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a market capitalization of $81.05 billion, a PE ratio of 18.45, a price-to-earnings-growth ratio of 2.12 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $12.07 EPS. Analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Insider Activity

In other news, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the completion of the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock worth $4,142,738 over the last quarter. Corporate insiders own 7.02% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Dodge & Cox raised its holdings in Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after buying an additional 1,502,198 shares during the period. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $1,012,296,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock worth $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. Nuveen LLC lifted its position in Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Regeneron Pharmaceuticals by 8,620.0% in the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares during the period. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.